Jiawei Shou

Sir Run Run Shaw Hospital — China

Medicine · Health Sciences

14h-index1.2kcitations33works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(9), Cancer Immunotherapy and Biomarkers(8), Lung Cancer Treatments and Mutations(8), Immunotherapy and Immune Responses(7), MicroRNA in disease regulation(5)

Publications33 total

Clinicopathological characteristics and treatment patterns of combined small-cell lung cancer: a real-world single-center study with a mini review
Frontiers in Immunology·2025Open Access
Real-world insights into advanced combined small cell lung cancer: Clinical characteristics and therapy.
Journal of Clinical Oncology·2025
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial
Cancer·2025· 1 citedOpen Access
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials
Advances in Therapy·2025
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.
Journal of Clinical Oncology·2024· 1 cited
Safety, tolerability, pharmacokinetics and clinical activity of AST-3424, an AKR1C3-activated bis-alkylating moiety prodrug, in subjects with advanced solid tumors in China: A phase I dose-escalation study.
Journal of Clinical Oncology·2024· 1 cited
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
Frontiers in Immunology·2022· 26 citedOpen Access
Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study
Journal of Clinical Medicine·2022· 14 citedOpen Access
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
Journal of Clinical Oncology·2022· 3 cited
Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response
Frontiers in Oncology·2022· 1 citedOpen Access
Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody
Frontiers in Molecular Biosciences·2021· 20 citedOpen Access
EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
Frontiers in Oncology·2021· 50 citedOpen Access
Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
Journal of Clinical Oncology·2021· 3 cited
Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
Frontiers in Oncology·2021· 3 citedOpen Access
Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
Scientific Reports·2020· 3 citedOpen Access
Corrigendum to “Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3” [Canc Lett 379 (2016) 124–133]
Cancer Letters·2020· 1 cited
A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors
Clinical Cancer Research·2020· 89 citedOpen Access
A microRNA disease signature associated with lymph node metastasis of lung adenocarcinoma
Mathematical Biosciences & Engineering·2020· 15 citedOpen Access
CircUBAP2-mediated competing endogenous RNA network modulates tumorigenesis in pancreatic adenocarcinoma
Aging·2019· 93 citedOpen Access
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (<i><scp>ALK</scp></i>)‐rearranged non‐small cell lung cancer
Cancer Science·2019· 31 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Hongming Pan(21), Weidong Han(16), Hongsen Li(13), Yong Fang(13), Liangkun You(12), Ju-Jun Xie(7), Xiaoyun Zhou(6), Chuangzhou Rao(6), Xinbing Sui(5), Shuqing Chen(5), Liming Jiang(5), Zhanggui Wang(4), Junlin Yao(4), Fan Mo(4), Jing Zhao(4), Sheng Jin(4), Qunyi Guo(4), Liqin Lu(4), Jing Zhao(3), Rongjie Zhao(3)